Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Mustang Bio, Inc. on December 26, 2024. The meeting was conducted virtually to elect directors and ratify the appointment of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Two proposals were presented and approved at the Annual Meeting:
- Proposal 1: Election of Directors. Seven directors were elected to serve until the 2025 annual meeting. All candidates received significant majority support with zero broker non-votes.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2024.
Voting Participation: Approximately 58% of all votes were represented at the meeting, constituting a quorum. As of the record date (December 4, 2024), the voting structure included 48,768,863 shares of Common Stock, 845,385 shares of Class A Common Stock, and 250,000 shares of Class A Preferred Stock.
Director Election Results
| Director | Votes For | Votes Withheld |
|---|---|---|
| Michael S. Weiss | 58,341,063 | 1,127,036 |
| Manuel Litchman, M.D. | 58,774,775 | 693,324 |
| Lindsay A. Rosenwald, M.D. | 58,357,788 | 1,110,311 |
| Neil Herskowitz | 58,737,407 | 730,692 |
| David Jin | 58,830,033 | 638,066 |
| Adam Chill | 58,881,270 | 586,829 |
| Michael Zelefsky, M.D. | 58,894,954 | 573,145 |
Auditor Ratification Results
| Category | Votes |
|---|---|
| For | 59,374,816 |
| Against | 62,690 |
| Abstentions | 30,593 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the Company's definitive Proxy Statement on Schedule 14A filed on December 6, 2024.
Key Facts for Investor Verification
- Verify the composition of the newly elected Board of Directors and their tenure until the 2025 meeting.
- Confirm the engagement of KPMG LLP for the 2024 fiscal year audit.
- Review the definitive Proxy Statement (Schedule 14A) for detailed biographies of directors and further context on the auditor ratification.
- Note the significant voting power held by Class A Preferred Stock holders (53,726,077 votes) compared to Common Stock holders.